Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pemetrexed + vandetanib
- Development stage
- Phase 3
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Pemetrexed + vandetanib is a combination therapy consisting of pemetrexed, an antifolate chemotherapy agent, and vandetanib, a multi-targeted tyrosine kinase inhibitor. Vandetanib inhibits vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and RET signaling pathways, while pemetrexed disrupts folate-dependent metabolic processes essential for cell replication. This combination was investigated primarily for second-line treatment of advanced non-small cell lung cancer (NSCLC).
- Brand names
- Alimta + Zactima
02
Targets
DHFR (Dihydrofolate reductase)EGFR (Epidermal growth factor receptor)GART (GAR transformylase)RET (Rearranged during transfection receptor tyrosine kinase)TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on pemetrexed + vandetanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pemetrexed + vandetanib.